After BioCryst fizzle, a new oral HAE player emerges
A new player in the search for an oral hereditary angioedema pill has received a major boost and show of confidence.
Pharvaris announced $66 million in Series B financing for its B2 receptor antagonist pill, nearly tripling the funding Attune Pharmaceuticals recently received in Series B for its own hereditary angioedema (HAE) pill. The money will fuel the company’s Phase I trial on its lead compound, PHA121, on healthy volunteers. The first subjects have already been dosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
